An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Janux Therapeutics (NASDAQ: JANX) will participate in two virtual investor conferences. The first is Cowen’s 5th Annual IO Next Summit on November 15, 2021, from 12:15-12:35 p.m. ET. The second is the Evercore ISI 4th Annual Health CONx Conference on December 2, 2021, from 2:40-3:00 p.m. ET. Archived replays of both sessions will be available for about 90 days on Janux's website. Janux is focused on developing innovative immunotherapies using its TRACTr and TRACIr platforms to treat cancer, with products targeting various cancer-specific antigens.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in fireside chats at two upcoming virtual investor conferences:
Cowen’s 5th Annual IO Next Summit
Forum: Fireside Chat
Date: Monday, November 15th, 2021
Time: 12:15-12:35 p.m. ET
Evercore ISI 4th Annual Health CONx Virtual Conference Forum: Fireside Chat
Date: Thursday, December 2nd, 2021
Time: 2:40 – 3:00 p.m. ET
Both fireside chats and subsequent archived replays may be accessed via the Investors & Media section of Janux’s website. An archived replay of both webcasts will be available on the website for approximately 90 days following the presentation.
About Janux Therapeutics Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), and its lead TRACIr program targeting PD-L1xCD28, with all of its programs currently in the IND-enabling or discovery stage. For more information, please visit www.januxrx.com.
Media:
Jessica Yingling, Ph.D.
Little Dog Communications Inc. jessica@litldog.com
(858) 344-8091
Investors:
Christina Tartaglia Stern Investor Relations, Inc.
christina@sternir.com
(212) 362-1200
Source: Janux Therapeutics, Inc.
FAQ
What dates will Janux Therapeutics participate in investor conferences?
Janux Therapeutics will participate in Cowen’s 5th Annual IO Next Summit on November 15, 2021, and the Evercore ISI 4th Annual Health CONx Conference on December 2, 2021.
What is the time slot for Janux's presentation at the Cowen Summit?
Janux's fireside chat at Cowen’s 5th Annual IO Next Summit is scheduled from 12:15 to 12:35 p.m. ET.
How can I access Janux Therapeutics' investor conference replays?
Archived replays of Janux's investor conference presentations will be available on their website for approximately 90 days after the events.
What platforms does Janux use for its cancer therapeutics?
Janux Therapeutics utilizes its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms for developing immunotherapies.
What are Janux's lead product candidates targeting?
Janux's lead product candidates target prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), among others.
